Litcius/Paper detail

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

Maud Velev, Cécile Dalban, Christine Chevreau, Gwénaëlle Gravis, Sylvie Négrier, Brigitte Laguerre, Marine Gross‐Goupil, Sylvain Ladoire, Delphine Borchiellini, Lionnel Geoffrois, Florence Joly, Frank Priou, Philippe Barthélémy, Mathieu Laramas, Berangère Narciso, Antoine Thiery-Vuillemin, Jean-François Berdah, Victoria Ferrari, Quentin Dominique Thomas, Cécile Mione, Hubert Curcio, Stéphane Oudard, Florence Tantot, Bernard Escudier, Sylvie Chabaud, Laurence Albigès, Constance Thibault

2023European Journal of Cancer17 citationsDOI

Topics & Concepts

Renal cell carcinomaNivolumabMedicineOncologyPhases of clinical researchInternal medicineCancerImmunotherapyToxicityRenal cell carcinoma treatmentManagement of metastatic bone diseaseCancer Immunotherapy and Biomarkers
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study | Litcius